Skip to main content

and
Your search also matched 1 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you.
results, e.g.

Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer’s Perspective

Include preview-only content
  1. Article

    Open Access

    Unmet Needs and Treatment Preference of Systemic Treatments for Moderate-to-Severe Psoriasis from the Perspectives of Patients and Dermatologists in China

    The treatment options for moderate to severe psoriasis (msPsO) in China have been greatly increased with the approvals of biologics. However, the unmet needs and treatment preferences of systemic treatments fo...

    Yehong Kuang, Yuzhen Li, Chengzhi Lv, Min Li, Zhenying Zhang in Dermatology and Therapy (2024)

  2. Article

    Open Access

    Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis

    Deucravacitinib, a newly approved oral medication for the treatment of patients with moderate to severe plaque psoriasis, demonstrated efficacy versus apremilast and placebo in two phase 3 randomized controlle...

    April W. Armstrong, Richard B. Warren, Yichen Zhong, Joe Zhuo in Dermatology and Therapy (2023)

  3. Article

    Open Access

    Suboptimal Clinical and Quality of Life Outcomes in Patients with Psoriasis Undertreated with Oral Therapies: International Physician and Patient Survey

    Psoriasis is a chronic, inflammatory, immune-mediated disease. This study assessed the time at which patients switched from a conventional oral systemic treatment to a biologic therapy; patient clinical and qu...

    Sydney Thai, Sophie Barlow, James Lucas, James Piercy in Dermatology and Therapy (2023)